CoChat
Sign Up
Cited by 166Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.

Fluid Biomarkers for Synaptic Dysfunction and Loss

Open access
Camporesi, Elena, Nilsson, Johanna, Brinkmalm, Ann, Becker, Bruno, Ashton, Nicholas J, Blennow, Kaj, Zetterberg, Henrik·2020·Biomarker Insights
DOI 10.1177/1177271920950319PMC PMC7444114
Open this paper in CoChat — free accountOpen PDF

Abstract

Synapses are the site for brain communication where information is transmitted between neurons and stored for memory formation. Synaptic degeneration is a global and early pathogenic event in neurodegenerative disorders with reduced levels of pre- and postsynaptic proteins being recognized as a core feature of Alzheimer's disease (AD) pathophysiology. Together with AD, other neurodegenerative and neurodevelopmental disorders show altered synaptic homeostasis as an important pathogenic event, and due to that, they are commonly referred to as synaptopathies. The exact mechanisms of synapse dysfunction in the different diseases are not well understood and their study would help understanding the pathogenic role of synaptic degeneration, as well as differences and commonalities among them and highlight candidate synaptic biomarkers for specific disorders. The assessment of synaptic proteins in cerebrospinal fluid (CSF), which can reflect synaptic dysfunction in patients with cognitive disorders, is a keen area of interest. Substantial research efforts are now directed toward the investigation of CSF synaptic pathology to improve the diagnosis of neurodegenerative disorders at an early stage as well as to monitor clinical progression. In this review, we will first summarize the pathological events that lead to synapse loss and then discuss the available data on established (eg, neurogranin, SNAP-25, synaptotagmin-1, GAP-43, and α-syn) and emerging (eg, synaptic vesicle glycoprotein 2A and neuronal pentraxins) CSF biomarkers for synapse dysfunction, while highlighting possible utilities, disease specificity, and technical challenges for their detection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1177271920950319

Cites

302 of 302 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Synaptic and neuronal biomarkers location. The picture is a schematic representation of the most studied synaptic biomarkers described in this review. As it can be noticed, most of the candidate biomarkers are localized presynaptically, with the exception of neurogranin and neuronal pentraxins (NPTX), which has also been described to be present presynaptically.260 Many proteins are involved in synaptic vesicle assembly and neurotransmitters release, like synaptotagmin-1 (syt 1), synaptophysin, SNAP-25, and SV2A.248 α-Synuclein (α-syn) can be found as a soluble form in the cytoplasm, but also associating with membrane lipids as, for instance, with synaptic vesicles and mitochondria.87 GAP-43 shows high density in the presynaptic terminal, where depending on its phosphorylation status, participates in neuronal growth modulating actin or in synaptic plasticity modulating synaptic vesicle trafficking.141 Together with actin filaments and microtubules, neurofilaments are cytoskeletal elements of the neurons, providing mechanical strength and stability.131 Tau protein, mainly expressed in axons, binds to tubulin and induce its polymerization into microtubules, which support axon outgrowth and elongation.261 α-syn indicates synuclein; DCV, dense-core vesicles; GAP-43, growth-associated protein 43; LTP, long-term potentiation; NPTX, neuronal pentraxin; SNAP-25, synaptosomal-associated protein 25. Figure made with www.biorender.com.
Figure 1. Synaptic and neuronal biomarkers location. The picture is a schematic representation of the most studied synaptic biomarkers described in this review. As it can be noticed, most of the candidate biomarkers are localized presynaptically, with the exception of neurogranin and neuronal pentraxins (NPTX), which has also been described to be present presynaptically.260 Many proteins are involved in synaptic vesicle assembly and neurotransmitters release, like synaptotagmin-1 (syt 1), synaptophysin, SNAP-25, and SV2A.248 α-Synuclein (α-syn) can be found as a soluble form in the cytoplasm, but also associating with membrane lipids as, for instance, with synaptic vesicles and mitochondria.87 GAP-43 shows high density in the presynaptic terminal, where depending on its phosphorylation status, participates in neuronal growth modulating actin or in synaptic plasticity modulating synaptic vesicle trafficking.141 Together with actin filaments and microtubules, neurofilaments are cytoskeletal elements of the neurons, providing mechanical strength and stability.131 Tau protein, mainly expressed in axons, binds to tubulin and induce its polymerization into microtubules, which support axon outgrowth and elongation.261 α-syn indicates synuclein; DCV, dense-core vesicles; GAP-43, growth-associated protein 43; LTP, long-term potentiation; NPTX, neuronal pentraxin; SNAP-25, synaptosomal-associated protein 25. Figure made with www.biorender.com.CC BY-NC · PubMed Central
Figure 2. Proteomic approaches in synaptic biomarkers discovery and validation. Proteomic studies can start with large explorative investigations in brain tissue, which might lead to the discovery of new candidate biomarkers. However, these studies can be seen as starting points, and they have no clinical utilities. Thus, investigations in CSF are needed to be able to translate the biomarker discovery into a tool of clinical use. Once the biomarker has been validated in CSF, further investigations can be carried in blood, a biofluid with higher accessibility and cheaper to use. On the other hand blood is further away from the brain and the targeted protein level might be susceptible to peripheral contribution, resulting in lower biomarker specificity and confounding results. A possible approach to overcome this problem is the use of plasma-derived neuronal exosomes. These investigations can be carried out with a targeted or non-targeted approach. In the diagram, pros and cons of both approaches are highlighted. ELISA indicates enzyme-linked immunosorbent assay; IP, immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; PRM, parallel reaction monitoring; SIMOA, single molecule array; WB, Western blot. Figure made with www.biorender.com.
Figure 2. Proteomic approaches in synaptic biomarkers discovery and validation. Proteomic studies can start with large explorative investigations in brain tissue, which might lead to the discovery of new candidate biomarkers. However, these studies can be seen as starting points, and they have no clinical utilities. Thus, investigations in CSF are needed to be able to translate the biomarker discovery into a tool of clinical use. Once the biomarker has been validated in CSF, further investigations can be carried in blood, a biofluid with higher accessibility and cheaper to use. On the other hand blood is further away from the brain and the targeted protein level might be susceptible to peripheral contribution, resulting in lower biomarker specificity and confounding results. A possible approach to overcome this problem is the use of plasma-derived neuronal exosomes. These investigations can be carried out with a targeted or non-targeted approach. In the diagram, pros and cons of both approaches are highlighted. ELISA indicates enzyme-linked immunosorbent assay; IP, immunoprecipitation; LC-MS, liquid chromatography-mass spectrometry; PRM, parallel reaction monitoring; SIMOA, single molecule array; WB, Western blot. Figure made with www.biorender.com.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 303 references

Research works printed but not linked: 7

  1. Dani M, 2018, Brain, 141, 2740
  2. 10.1212/WNL.56.1.127 · DOI · Paper page
  3. Baba M, 1998, Am J Pathol, 152, 879
  4. Filippi L, 2018, Am J Nucl Med Mol Imaging, 8, 268
  5. Zhou B, 2015, Parkinsons Dis, 2015, 567386
  6. Blennow K, 1995, Dementia, 6, 306
  7. Foote M, 2012, Int J Biochem Mol Biol, 3, 152

Cited by

Sorted by citations

See all 166

Related

Metadata

Authors
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H.
Affiliations
  • University of Gothenburg (SE)
  • Sahlgrenska University Hospital (SE)
  • King's College London (GB)
Corresponding author
Camporesi, Elena
ORCID
Venue
Biomarker Insights
Publisher
SAGE Publications
Published
2020-01
Volume
15
Pages
117727192095031
ISSN
1177-2719 (ISSN-L)
DOI
10.1177/1177271920950319
PMC
PMC7444114
OpenAlex
W3080191672
Cited by
165
References
303
Citations by year
2026: 19 · 2025: 30 · 2024: 33 · 2023: 23 · 2022: 35 · 2021: 23 · 2020: 2
FWCI
2.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomarker Insights (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
synaptic dysfunction, synaptic loss, cerebrospinal fluid biomarkers, synaptopathy, neurodegenerative diseases, Alzheimer's disease, neurogranin, SNAP-25, synaptotagmin-1, GAP-43, alpha-synuclein, SV2A, synaptic proteins, early diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review